Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy


Colorectal Cancer

What is the purpose of this trial?

RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Monoclonal antibodies, such as cetuximab and ramucirumab, can block tumor growth
in different ways. Some block the ability of tumor cells to grow and spread. Others find
tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab and
ramucirumab may also stop the growth of colorectal cancer by blocking blood flow to the
tumor. It is not yet know whether giving cetuximab and irinotecan hydrochloride together is
more effective with or without ramucirumab in treating colorectal cancer.

PURPOSE: This randomized phase II trial is studying the side effects and how well giving
cetuximab and irinotecan hydrochloride with or without ramucirumab work in treating patients
with advanced colorectal cancer with progressive disease after treatment with
bevacizumab-containing chemotherapy.

Participation Guidelines

18 Years - N/A

Click here for detailed information about who can participate in this trial.

National Cancer Institute (NCI)
Pam Cogliano
November 2010
Last Updated:
September 19, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01079780